Blesstia Pharmaceutical

What Blesstia Pharmaceutical does

Blesstia Pharmaceutical (legal entity Blesstia Ltd) is a privately held Cypriot pharmaceutical company founded in 2008 and headquartered at 176b Giannou Kranidioti Avenue, Nicosia. The company develops and manufactures two product lines: (1) Homeopathic Synthesis intermediate products marketed under the BLESSTIA SYNTHESIS brand, comprising 86 proprietary formulations spanning therapeutic categories such as immune system, muscular system, digestive system, skin/respiration/ears, psychological, metabolic, and age-related support; and (2) Biopharmaceuticals. All products are manufactured under cGMP certification issued by the Ministry of Health and Ministry of Agriculture of Cyprus, and the company is registered in the EudraGMDP database operated by the European Medicines Agency, placing it within the European GMP-certified manufacturer network.

The company's scientific direction is provided by an international team of homeopathic Medical Doctors with combined clinical experience exceeding 45 years, and its go-to-market is exclusively channel-led: pharmacists are the sole distribution partners, performing pharmacotechnical compounding procedures to convert Blesstia's intermediate formulations into officinal homeopathic medicines dispensed to patients. The firm targets both licensed pharmacists (16,210 reported as active) and broader healthcare professionals and therapists (117,163 reported informed) through digital marketing, scientific documentation (repertorizing hints, materia medica references), clinical research collaborations, medical seminars, and special certification courses. Headcount is stated at 51–100 employees.

The revenue model is a one-time product sale of intermediate formulations to pharmacists, with ongoing reorder dynamics across 86 SKUs. No pricing details, revenue figures, funding history, external investors, parent company, M&A activity, or digital platform capabilities are publicly disclosed. The company is privately held, founder-controlled, and reports no AI, software-as-a-service, or digital product surface beyond a corporate website and a Facebook profile.

Name

Blesstia Pharmaceutical

Legal name

Blesstia Ltd

Website

https://www.blesstia.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Blesstia Pharmaceutical is a Cyprus-based private manufacturer of 86 proprietary BLESSTIA SYNTHESIS homeopathic intermediate formulations and biopharmaceuticals, sold B2B to a network of 16,210 pharmacists across Europe who compound them into officinal medicines for patients.

Ownership category

akta.pro rank

Product category

Homeopathic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Homeopathic synthesis
• Pharmaceutical manufacturing
• Biopharmaceutical products
• CGMP certified medicines
• Compounding intermediates

Headquarters

HQ city

Nicosia

HQ country

Cyprus

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. Homeopathic Synthesis Products: Manufacture and sale of advanced homeopathic intermediate products for pharmacists to compound into officinal homeopathic medicines. The company produces 86 distinct BLESSTIA SYNTHESIS formulations across various therapeutic categories including immune system, muscular system, digestive system, skin/respiration/ears, and more.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Blesstia Pharmaceutical is a composite pharmaceutical company that develops and produces two product lines: (1) Homeopathic Synthesis intermediate products for pharmacists — a proprietary portfolio of 86 BLESSTIA SYNTHESIS homeopathic pharmaceutical formulations that serve as starting materials for compounding officinal homeopathic medicines; and (2) Biopharmaceuticals. All products are manufactured under cGMP certification issued by the Ministry of Health and Ministry of Agriculture of Cyprus, with the company registered in the EudraGMDP database operated by the European Medicines Agency (EMA). Scientific direction is provided by an international team of homeopathic Medical Doctors with over 45 years of clinical experience.

Product overview

Blesstia Pharmaceutical is a composite pharmaceutical company that develops and produces two distinct product lines: (1) Homeopathic Synthesis intermediate products for Pharmacists - specifically 86 innovative homeopathic pharmaceutical formulations under the BLESSTIA SYNTHESIS brand, which serve as starting materials for the compounding of officinal homeopathic medicines; and (2) Biopharmaceuticals. The company operates under cGMP certification and is registered in the EudraGMDP database. The scientific direction is guided by an international team of homeopathic Medical Doctors with over 45 years of clinical experience. Products are distributed through pharmacists and target various therapeutic areas including muscular system support, immune system, digestive health, metabolic functions, and skin/respiratory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• BLESSTIA SYNTHESIS - 86 Homeopathic Pharmaceutical Formulations A proprietary portfolio of 86 innovative homeopathic synthesis intermediate products developed for pharmacists to compound into officinal homeopathic medicines. The formulations cover therapeutic categories including immune system, muscular system, digestive system, skin/respiration/ears, and other body systems, designed to support the organism without diagnostic insecurity, inaccurate selection of idiosyncratic remedy, or dependency on antidoting factors.
• Biopharmaceuticals A line of biopharmaceutical products developed and produced by Blesstia alongside its homeopathic synthesis product line, manufactured under cGMP certification.
• BLESSTIA SYNTHESIS WYETHIA 116 Homeopathic synthesis product for support of the organism with muscle discomforts from continuous work at the computer, uncomfortable body posture, or prolonged immobility.
• BLESSTIA SYNTHESIS VERATRUM 119 Homeopathic synthesis product for support of the organism that expresses paroxysmal feeling of dizziness and rotation of functional origin.
• BLESSTIA SYNTHESIS TUSSILAGO 44 Homeopathic synthesis product for support of the organism for intensive daily tonification.
• BLESSTIA SYNTHESIS TRIOSTEUM 113 Homeopathic synthesis product for support of the organism for the tendons.
• BLESSTIA SYNTHESIS TONGA 29 Homeopathic synthesis product for support of the organism for daily invigoration. Dosage: 3 tablets daily orally. No side effects manifested and no synergy observed when administered with other medicines.
• BLESSTIA SYNTHESIS THUJA 60 Homeopathic synthesis product for support of the organism that manifests benign tumors. Used for warts, fungoid growths, condyloma, and proud flesh conditions.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Boiron: World's largest manufacturer of homeopathic medicines, with a broad portfolio of homeopathic dosage forms sold through pharmacies. Directly comparable to Blesstia as a cGMP homeopathic pharmaceutical producer using pharmacy channels, but at vastly greater scale and geographic reach.
• Deutsche Homöopathie-Union (DHU): Leading German manufacturer of homeopathic medicines sold primarily through pharmacies. Closely comparable in business model — pharmacy-channel homeopathic manufacturing under strict quality standards — making it a direct European peer for Blesstia.
• Schwabe Group: Major German-based manufacturer of homeopathic and phytopharmaceutical preparations distributed through pharmacies globally. Comparable to Blesstia as a vertically integrated homeopathic/phytopharmaceutical producer serving the pharmacy channel.
• Biologische Heilmittel Heel: German manufacturer of combination homeopathic and biologic medicines, distributed through healthcare professionals and pharmacies. Comparable to Blesstia for its regulated homeopathic/biopharmaceutical manufacturing and pharmacy-led distribution.
• Guna: Italian manufacturer of homeopathic medicines (low-dose medicine) sold primarily through pharmacies, with a comparable pharmacist-channel GTM and focus on advanced/homeopathic formulations.
• Nelsons (Nelson Pharmacia): UK-based homeopathic pharmacy producing and distributing homeopathic remedies through pharmacy and practitioner channels. Comparable business model centred on pharmacy distribution of homeopathic preparations.

Broad incumbents

• Weleda: Producer of anthroposophic and homeopathic medicines alongside natural body care products, distributed through pharmacies and specialist retailers. Comparable in regulated homeopathic manufacturing but with a much broader consumer-care portfolio.

Emerging players

• Ainsworths: UK-based specialist homeopathic pharmacy manufacturing bespoke and stock remedies. Comparable niche player operating at smaller scale than Boiron/Schwabe, sharing Blesstia's specialised compounding-focused model.
• Hahnemann Laboratories: US-based homeopathic manufacturer producing homeopathic medicines in various dosage forms. Comparable as a regulated homeopathic manufacturing peer at smaller scale than global incumbents.

Regional players

• Heel Spain / Heel España: Regional affiliate of Biologische Heilmittel Heel distributing homeopathic/biologic medicines in Spain and Portugal. Comparable as a pharmacy-channel homeopathic manufacturer with overlapping product categories to Blesstia's synthesis line.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/blesstiapharma
• Facebookfacebook.com/blesstia
• LinkedInlinkedin.com/company/blesstia-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blesstia Pharmaceutical